361 related articles for article (PubMed ID: 18443903)
1. Cost-effectiveness analysis of adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for node-positive breast cancer: modeling the downstream effects.
Au HJ; Golmohammadi K; Younis T; Verma S; Chia S; Fassbender K; Jacobs P
Breast Cancer Res Treat; 2009 Apr; 114(3):579-87. PubMed ID: 18443903
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness analysis of adjuvant therapy for node positive breast cancer in Korea: docetaxel, doxorubicin and cyclophosphamide (TAC) versus fluorouracil, doxorubicin and cyclophosphamide (FAC).
Lee SG; Jee YG; Chung HC; Kim SB; Ro J; Im YH; Im SA; Seo JH
Breast Cancer Res Treat; 2009 Apr; 114(3):589-95. PubMed ID: 18437555
[TBL] [Abstract][Full Text] [Related]
3. Docetaxel for the adjuvant treatment of early node-positive breast cancer: a single technology appraisal.
Chilcott J; Lloyd Jones M; Wilkinson A
Health Technol Assess; 2009 Jun; 13 Suppl 1():7-13. PubMed ID: 19567208
[TBL] [Abstract][Full Text] [Related]
4. Docetaxel in combination with doxorubicin and cyclophosphamide as adjuvant treatment for early node-positive breast cancer: a cost-effectiveness and cost-utility analysis.
Wolowacz SE; Cameron DA; Tate HC; Bagust A
J Clin Oncol; 2008 Feb; 26(6):925-33. PubMed ID: 18281666
[TBL] [Abstract][Full Text] [Related]
5. Economic evaluation of intensive chemotherapy with prophylactic granulocyte colony-stimulating factor for patients with high-risk early breast cancer in Japan.
Ishiguro H; Kondo M; Hoshi SL; Takada M; Nakamura S; Teramukai S; Yanagihara K; Toi M
Clin Ther; 2010 Feb; 32(2):311-26. PubMed ID: 20206789
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial.
Mackey JR; Martin M; Pienkowski T; Rolski J; Guastalla JP; Sami A; Glaspy J; Juhos E; Wardley A; Fornander T; Hainsworth J; Coleman R; Modiano MR; Vinholes J; Pinter T; Rodríguez-Lescure A; Colwell B; Whitlock P; Provencher L; Laing K; Walde D; Price C; Hugh JC; Childs BH; Bassi K; Lindsay MA; Wilson V; Rupin M; Houé V; Vogel C;
Lancet Oncol; 2013 Jan; 14(1):72-80. PubMed ID: 23246022
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant chemotherapy for breast cancer: a cost-utility analysis of FEC-D vs. FEC 100.
Younis T; Rayson D; Sellon M; Skedgel C
Breast Cancer Res Treat; 2008 Sep; 111(2):261-7. PubMed ID: 17914669
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant docetaxel for high-risk, node-negative breast cancer.
Martín M; Seguí MA; Antón A; Ruiz A; Ramos M; Adrover E; Aranda I; Rodríguez-Lescure A; Grosse R; Calvo L; Barnadas A; Isla D; Martinez del Prado P; Ruiz Borrego M; Zaluski J; Arcusa A; Muñoz M; López Vega JM; Mel JR; Munarriz B; Llorca C; Jara C; Alba E; Florián J; Li J; López García-Asenjo JA; Sáez A; Rios MJ; Almenar S; Peiró G; Lluch A;
N Engl J Med; 2010 Dec; 363(23):2200-10. PubMed ID: 21121833
[TBL] [Abstract][Full Text] [Related]
9. Cost-utility analysis of adjuvant therapies for breast cancer in Iran.
Bastani P; Kiadaliri AA
Int J Technol Assess Health Care; 2012 Apr; 28(2):110-4. PubMed ID: 22559752
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer.
Delea TE; Karnon J; Smith RE; Johnston SR; Brandman J; Sung JC; Gross PE
Am J Manag Care; 2006 Jul; 12(7):374-86. PubMed ID: 16834524
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant docetaxel for node-positive breast cancer.
Martin M; Pienkowski T; Mackey J; Pawlicki M; Guastalla JP; Weaver C; Tomiak E; Al-Tweigeri T; Chap L; Juhos E; Guevin R; Howell A; Fornander T; Hainsworth J; Coleman R; Vinholes J; Modiano M; Pinter T; Tang SC; Colwell B; Prady C; Provencher L; Walde D; Rodriguez-Lescure A; Hugh J; Loret C; Rupin M; Blitz S; Jacobs P; Murawsky M; Riva A; Vogel C;
N Engl J Med; 2005 Jun; 352(22):2302-13. PubMed ID: 15930421
[TBL] [Abstract][Full Text] [Related]
12. Fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel as adjuvant therapy for high-risk, node-negative breast cancer: results from the GEICAM/2003-02 study.
Martín M; Ruiz A; Ruiz Borrego M; Barnadas A; González S; Calvo L; Margelí Vila M; Antón A; Rodríguez-Lescure A; Seguí-Palmer MA; Muñoz-Mateu M; Dorca Ribugent J; López-Vega JM; Jara C; Espinosa E; Mendiola Fernández C; Andrés R; Ribelles N; Plazaola A; Sánchez-Rovira P; Salvador Bofill J; Crespo C; Carabantes FJ; Servitja S; Chacón JI; Rodríguez CA; Hernando B; Álvarez I; Carrasco E; Lluch A
J Clin Oncol; 2013 Jul; 31(20):2593-9. PubMed ID: 23733779
[TBL] [Abstract][Full Text] [Related]
13. The use of paclitaxel in the management of early stage breast cancer.
Griffin S; Dunn G; Palmer S; Macfarlane K; Brent S; Dyker A; Erhorn S; Humphries C; White S; Horsley W; Ferrie L; Thomas S
Health Technol Assess; 2009 Jun; 13 Suppl 1():15-22. PubMed ID: 19567209
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of letrozole in the extended adjuvant treatment of women with early breast cancer.
El Ouagari K; Karnon J; Delea T; Talbot W; Brandman J
Breast Cancer Res Treat; 2007 Jan; 101(1):37-49. PubMed ID: 16821085
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness analysis of docetaxel (Taxotere) vs. 5-fluorouracil in combined therapy in the initial phases of breast cancer.
Martín-Jiménez M; Rodríguez-Lescure A; Ruiz-Borrego M; Seguí-Palmer MA; Brosa-Riestra M
Clin Transl Oncol; 2009 Jan; 11(1):41-7. PubMed ID: 19155203
[TBL] [Abstract][Full Text] [Related]
16. Capecitabine plus docetaxel combination therapy.
Verma S; Maraninchi D; O'Shaughnessy J; Jamieson C; Jones S; Martín M; McKendrick J; Miles D; Twelves C; Hornberger J
Cancer; 2005 Jun; 103(12):2455-65. PubMed ID: 15892043
[TBL] [Abstract][Full Text] [Related]
17. Modelling the cost-effectiveness of adjuvant lapatinib for early-stage breast cancer.
Candon D; Healy J; Crown J
Acta Oncol; 2014 Feb; 53(2):201-8. PubMed ID: 24125103
[TBL] [Abstract][Full Text] [Related]
18. A comparison of the outcomes of non-randomised chemotherapy regimens in node positive breast cancer.
Kuru B; Camlibel M; Dinc S; Gulcelik MA; Atalay C; Alagol H
J Exp Clin Cancer Res; 2005 Sep; 24(3):363-72. PubMed ID: 16270522
[TBL] [Abstract][Full Text] [Related]
19. Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancer.
Liberato NL; Marchetti M; Barosi G
J Clin Oncol; 2007 Feb; 25(6):625-33. PubMed ID: 17308267
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of combination versus sequential docetaxel and carboplatin for the treatment of platinum-sensitive, recurrent ovarian cancer.
Havrilesky LJ; Pokrzywinski R; Revicki D; Higgins RV; Nycum LR; Kohler MF; Berchuck A; Myers ER; Secord AA
Cancer; 2012 Jan; 118(2):386-91. PubMed ID: 21598242
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
